Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma.

Authors

• Joshua Richter
• Yvonne Efebera, OhioHealth
• Habte Yimer
• Pragya Shukla
• Venediktos Kapetanakis
• Molly Purser
• Natalie Boytsov
• Nick Ballew

Document Type

Article

Publication Title

American journal of hematology

DOI

10.1002/ajh.70408

Publication Date

6-12-2026

Recommended Citation

Richter J, Efebera Y, Yimer H, Shukla P, Kapetanakis V, Purser M, Boytsov N, Ballew N. Comparative Efficacy of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone Versus Standards of Care in Patients With Third-Line or Later Relapsed/Refractory Multiple Myeloma. Am J Hematol. 2026 Jun 12. doi: 10.1002/ajh.70408. Epub ahead of print. PMID: 42286808.